top of page


Impactful technology

February 2024


Study Demonstrates the Potential of HelixBind’s RaPID/BSI Assay to Accurately Identify Bloodstream Infections Associated with Sepsis in Patients Undergoing Antimicrobial Treatment

February 2024


HelixBind Named a Phase 2 Winner of the LymeX Diagnostics Prize

by HHS and Steven & Alexandra Cohen Foundation

Closeup of a Petri Dish
December 2023


USPTO issues HelixBind patent US 11,840,721 covering

improved methods for detecting microbial infections.

Test Tubes
December 2023


HelixBind announces the award of $6 million of non-dilutive funding in 2023

to advance the company's RaPID diagnostic platform.

august 2023

USPTO issues HelixBind patent US 11,713,330 covering methods for ultrasensitive direct detection

of microorganisms, including Borrelia, the causative pathogen of Lyme Disease.

February 2023


USPTO issues HelixBind patent US 11,590,507 covering reagent carriers for fluidic systems.

December 2022

HelixBind announces $9 million in non-dilutive financing from the NIH in 2022 to support the

development of assays for the direct detection and identification of infections.

November 2022


HelixBind selected as Phase 1 winner of the LymeX Diagnostics Prize competition from

the U.S. Department of Health and Human Services and the Steven & Alexandra Cohen Foundation.


USPTO issues HelixBind patent US 11,414,712 covering methods to identify microbial species

direct from complex specimens, such as blood.

Science Lab
August 2022

Japanese Patent Office (JPO) issues HelixBind patent JP 7073328 covering multiple aspects

of HelixBind’s sample-to-answer automated device.

March 2022

Japanese Patent Office (JPO) issues HelixBind patent JP 7046603 covering the company’s method

for the identification of microbial infections directly from human specimens.

MARCH 2022

The China National Intellectual Property Administration (CNIPA) issues HelixBind

patent number CN 109414695 covering certain aspects of its integrated fluidic devices.

Test Tubes
august 2021

USPTO issues HelixBind patent US 11,091,814 covering the methods

to detect bacterial and/or fungal genomic material in a sample.

June 2021

HelixBind Awarded $3MM NIH Grant to Support Testing of Its

RaPID Diagnostic Platform for Invasive Infections Associated with Sepsis.

Closeup of a Petri Dish


FDA Grants HelixBind Breakthrough Device Designation for RaPID Sepsis Test.

bottom of page